Tubal Patency Assessment (Focusing on Hysterosalpingo-Contrast Sonography)
Arianna D'Angelo, Nazar N. Amso in Ultrasound in Assisted Reproduction and Early Pregnancy, 2020
Optison (GE Healthcare, Chicago, Illinois) is another human albumin–based contrast solution. It contains microspheres of heat-treated human albumin containing perflutren gas as the active substance. Because it is albumin-based, the solution is potentially allergenic.
Incomplete thermal ablation of tumors promotes increased tumorigenesis
Published in International Journal of Hyperthermia, 2021
Aurelia Markezana, S. Nahum Goldberg, Gaurav Kumar, Elina Zorde-Khvalevsky, Svetlana Gourevtich, Nir Rozenblum, Eithan Galun, Muneeb Ahmed
In this study, we further noted that the secretion of pro-tumorigenic cytokines and the resultant tumorigenesis occur relatively rapidly (i.e., within hours to days) after treatment. Thus, the current results suggest that it may be warranted to attempt to identify and eliminate any visible residual tumor as soon as possible, ideally in the initial ablation session. This would support the contention of those promoting multiple methods of intra-procedural assessment including contrast enhanced ultrasound, cone bean CT, or MR thermal monitoring, and the timing of the first post-ablation imaging follow-up [30]. Furthermore, our study raises concern that palliative treatment alone without additional adjuvant therapy may not be prudent, particularly in cases were residual tumors – visible or otherwise – is highly suspected. Moreover, any increase in tumorigenesis from residual tumor post ablation would call into question the potential appropriateness of using ablation as a palliative treatment or stimulator for immunotherapy.
Comparison of outcomes of hysteroscopic myomectomy of type 2 submucous fibroids greater than 4 cm in diameter via pretreatment with HIFU or GnRH-a
Published in International Journal of Hyperthermia, 2021
Ping Liao, Jing Jiang, Yu-hua Zeng, Yan Chen, Min Yong, Da-cheng Qu, Hong-gui Zhou
The protocol of HIFU treatment was described in a previously study [15]. Briefly, HIFU treatment was performed under conscious sedation. The JC HIFU tumor therapeutic system (Chongqing Haifu Medical Technology, Co., Ltd., Chongqing, China) was used for HIFU treatment. Therapeutic ultrasound energy was generated by a transducer with a frequency of 1.0 MHz. A Mylab 70 ultrasound imaging device (Esaote, Genova, Italy) was used to provide real-time imaging to monitor the treatment. The patients were placed in a prone position on the HIFU table, with the anterior abdominal wall in contact with degassed water. A degassed water balloon was placed between the abdominal wall and the transducer to help compress or push the bowel away from the acoustic pathway. Focal point was selected, and power set between 300–400 watts. During the procedure, the power was adjusted based on patient feedback and gray scale changes. This process was repeated until there was an absence of blood supply under contrast-enhanced ultrasound. The patients' vital signs such as heart rate, blood pressure, respiration, oxygen saturation were monitored during the procedure. The following formula: V = (1/6) × π ×D1 × D2 × D3 was used to calculated the volume of the fibroids, the non-perfused volume, and the volume of the uterus [16].
The impact of gestational sac size on the effectiveness and safety of high intensity focused ultrasound combined with ultrasound-guided suction curettage treatment for caesarean scar pregnancy
Published in International Journal of Hyperthermia, 2018
Yuqi Zhang, Cai Zhang, Jia He, Jin Bai, Lian Zhang
The procedure of HIFU ablation was conducted under conscious sedation with fentanyl (1 μg/kg) and midazolam hydrochloride (20 μg/kg). Each patient was positioned prone on the HIFU system, with the abdominal wall soaked in degassed water over the transducer in the sealed reservoir. During treatment, the focus was placed close to the embedding area of the gestational sac in the center slice at the beginning of the HIFU ablation procedure. Sonication power ranged from 300 to 400 W. Termination of HIFU ablation for CSP occurred when: (1) obvious grey scale change in the target area was observed through a real-time US-monitor; (2) blood flow signal of gestational sac embedding area disappeared or was significantly reduced in the colour Doppler. Contrast-enhanced micro-bubble agent (SonoVue, Bracco, Milan, Italy) was used 10 min pre- and immediately post-HIFU treatment to evaluate the ablation area and changes of blood supply around the gestational sac. The therapeutic effect was confirmed by contrast-enhanced ultrasound post-HIFU: (1) a non-perfused volume was observed in gestational sac embedding area; (2) blood supply around the gestational sac, especially the embedding area, disappeared or significantly reduced (Figure 2).
Related Knowledge Centers
- Perfusion
- Tissue
- Ultrasound
- Circulatory System
- Hemodynamics
- Contrast Agent
- Medical Ultrasound
- Microbubble
- Echogenicity
- Backscatter